8 Results for "

PD-0325901

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "PD-0325901" in MCE Product Catalog:

159
159 Publications Verification
Cat. No.: HY-10254
CAS No.: 391210-10-9
Purity:  99.95%
Synonyms: PD0325901; PD325901
Target:  

MEK Autophagy Apoptosis

Research Areas:  

Cancer

Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM. Mirdametinib exhibits a Ki app of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-131295
CAS No.: 2581116-22-3
Purity:  98.62%
Research Areas:  

Cancer

PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-10254G
CAS No.: 391210-10-9
Synonyms: PD0325901 (GMP); PD325901 (GMP)
Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive MEK inhibitor .
loading...
    loading...
Cat. No.: HY-130602
CAS No.: 2672512-44-4
Purity:  99.72%
Target:  

PROTACs MEK

Research Areas:  

Cancer

MS432 is a first-in-class and highly selective PD0325901-based von Hippel-Lindau-recruiting PROTAC degrader for MEK1 and MEK2. MS432 displays good plasma exposure in mice, exhibiting DC50 values of 31 nM and 17 nM for MEK1, MEK2 in HT29 cells respectively .
loading...
    loading...
Cat. No.: HY-10508
CAS No.: 1003216-77-0
Target:  

MEK

Research Areas:  

Cancer

(R)-PD 0325901CL is an isomer of PD 0325901CL. PD 0325901CL is a selective inhibitor of mitogen-activated protein kinase kinase (MEK) involved in cancer research. PD 0325901CL inhibits the growth of cancer cells in vitro and in vivo .
loading...
    loading...
Cat. No.: HY-10254R
CAS No.: 391210-10-9
Synonyms: PD0325901 (Standard); PD325901 (Standard)
Research Areas:  

Cancer

Mirdametinib (Standard) is the analytical standard of Mirdametinib (HY-10254). This product is intended for research and analytical applications. Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM. Mirdametinib exhibits a Kiapp of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts .
loading...
    loading...
Cat. No.: HY-130642
CAS No.: 2836297-55-1
Purity:  98.02%
Research Areas:  

Cancer

(S,R,S)-AHPC-Me-C10-Br is a synthesized E3 ligase ligand-linker conjugate. (S,R,S)-AHPC-Me-C10-Br incorporates a VHL E3 ligase linker and MS432 based on the MEK1/2 inhibitor PD0325901 .
loading...
    loading...
Cat. No.: HY-13810
CAS No.: 1111636-35-1
Target:  

Raf

Research Areas:  

Cancer

PF-04880594 is a potent and selective RAF inhibitor. PF-04880594 inhibits both wild-type and mutant BRAF and CRAF. PF-04880594 shows antitumor activity .
loading...
    loading...